The Efficacy and Safety of BI 2536, a Novel Plk-1 Inhibitor, in Patients with Stage IIIB/IV Non-small Cell Lung Cancer Who Had Relapsed after, or Failed, Chemotherapy: Results from an Open-Label, Randomized Phase II Clinical Trial
Martin Sebastian(Klinik und Poliklinik für Psychosomatische Medizin und Psychotherapie), Martin Reck(LungenClinic Grosshansdorf), Cornelius F. Waller(University of Freiburg), C. Kortsik(St. Bernward Krankenhaus), Norbert Frickhofen(Helios Dr. Horst Schmidt Kliniken Wiesbaden), Martin Schüler(Essen University Hospital), Holger Fritsch(Boehringer Ingelheim (Germany)), Birgit Gaschler‐Markefski(Boehringer Ingelheim (Germany)), Gertraud Hanft(Boehringer Ingelheim (Germany)), Gerd Munzert(Boehringer Ingelheim (Germany)), Joachim von Pawel(Asklepios Fachkliniken München-Gauting)
Cited by 111Open Access
Abstract
Related Papers
No related papers found
Powered by citation graph analysis